by Jen Hodson | Nov 13, 2019 | Articles
.post-meta {display:none;} BioWorld MedTech By Meg Bryant Nanthealth Inc. has received U.S. FDA clearance for a whole exome sequencing test to determine overall tumor mutational burden (TMB) in cancer tissue. Known as Omics Core, the first-of-its-kind in vitro...
by Jen Hodson | Nov 12, 2019 | Press Releases
Landmark FDA clearance of whole exome sequencing in vitro diagnostic (IVD) test reporting overall tumor mutation burden (TMB) by sequencing 19,396 protein-coding genes (whole exome) targeting 39 million base pairs (39 Mb) of the human genome from patient tumor and...
by Jen Hodson | Nov 7, 2019 | Press Releases
Q3 Financial Highlights: Total revenue was $22.4 million SaaS revenue was $18.3 million, up 15% from Q3 2018 Total gross margin increased to 63% from 50% in Q3 2018 Company was cash flow positive, with cash growing by $2.3 million from Q2 2019 to $9.3 million at Q3...
by Jen Hodson | Oct 30, 2019 | Press Releases
Culver City, Calif. – October 30, 2019 — NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2019 third quarter on Thursday, November 7, 2019, after market...
by Jen Hodson | Oct 25, 2019 | Press Releases
Attendees to Learn about Product Upgrades, Share Experiences and Network with Colleagues Mountain View, CA – October 25, 2019 – NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, will be sponsoring a Connected Care user...
